CD19 Assay Portfolio Service
Background Therapeutics Featured Services Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Creative Biolabs has extensive experience in the field of immuno-oncology (IO). Our in-house experts specialize in the full spectrum of IO research and have the capability to provide comprehensive CD19 assay portfolio services. We are committed to supporting our customers' biopharmaceutical development pipeline with our expertise to achieve the success of the project.
The Background of CD19
CD19 (B-lymphocyte surface antigen B4) is a type I transmembrane glycoprotein of 95 kD, belonging to the immunoglobulin (Ig) superfamily. Alongside complement receptor CD21, CD81 (TAPA-1), as well as CD225, CD19 forms a multimolecular complex and functions as the dominant signaling component on the surface of mature B cells.
CD19 Targeted Therapeutics
CD19 antigen is considered to be a specific B-cell marker and has been a preferred target for the development of targeted therapeutics against B-cell malignancies due to the expression pattern on most B-cell malignancies. What is more, CD19 plays a crucial role in maintaining the balance between humoral, antigen-induced response and tolerance induction, and has been used in the therapy of autoimmune diseases. Currently, the rationale for CD19 as a molecular target in these disease settings includes the applications, such as CD19 antibodies, anti-CD19 CARs, ADCs and so on.
CBL's Assay Portfolio Services
Creative Biolabs has robustly developed in vitro and in vivo platforms to provide reproducible CD19 targeted assays for our clients all over the world. We are dedicated to designing comprehensive research practices and handling high-quality studies to support your biopharmaceutical development pipeline. We can provide the following assays for our clients, but not limited to:
-
In Vitro Assays:
-
CD19-targeted leads screening;
-
Binding affinity test;
-
Epitope mapping;
-
Functional assay;
-
In Vivo Assays:
-
Model construction;
-
PK/PD study;
Publication
This study tackles key limitations of current CAR-T therapies by developing universal allogeneic hypoimmune (HIP) CAR-T cells. Using CRISPR-Cas9, researchers disrupted B2M, CIITA, and TRAC genes while expressing CD47 and anti-CD19 CAR to create immune-evasive T cells. In immunocompetent humanized mice, these HIP CAR-T cells showed superior persistence, expansion, and tumor clearance compared to conventional allogeneic versions, while maintaining equal tumor-killing efficacy in immunodeficient models. The team also implemented a safety switch using CD47-targeting fusion proteins for controlled cell elimination. These findings address major challenges of current approaches: autologous therapy's high costs/delays and allogeneic therapy's immune rejection issues. The HIP platform demonstrates potential to combine the durability of autologous products with the scalability of allogeneic therapies, offering a promising solution for more accessible, effective cancer treatment.
Fig.1 Flow cytometric analysis of T cell and CAR T cell phenotypes.1
Why Choose Us?
Creative Biolabs is a global leader in immuno-oncology, and our CD19 assay portfolio is built on a foundation of scientific excellence and quality. Their services are distinguished by deep expertise, flexible and customized solutions, and a commitment to providing clinically relevant, high-precision data. The portfolio provides data-driven solutions to critical challenges, enabling precise characterization of binding affinity and kinetics of therapeutic candidates, and evaluating the mechanism of action, efficacy, and safety profiles. They also offer advanced biomarker analysis services for patient monitoring and overcoming resistance mechanisms, delivering reliable and reproducible data to accelerate projects from the bench to the bedside.
Creative Biolabs' scientists are dedicated to bringing together years of valuable experience to help our clients shorten the project journey. For further details, please don't hesitate to contact us.
Frequently Asked Questions
Q1: Can you help me develop a custom assay for my unique CAR-T construct?
A1: Absolutely. Our team specializes in designing and optimizing custom assays. We work closely with you to understand your specific construct and research goals to develop a bespoke assay that delivers precise and relevant data.
Q2: How do your assays compare to standard commercial kits?
A2: Unlike off-the-shelf kits, our services offer a fully customized and validated approach. We provide expert consultation, tailored protocols, and in-depth data interpretation, ensuring the results are highly specific and relevant to your unique project, saving you time and resources.
Q3: How do your services help in overcoming therapy resistance?
A3: Our comprehensive portfolio, particularly our biomarker analysis and functional assays, can help you identify mechanisms of resistance, such as CD19 antigen downregulation or T-cell exhaustion. This data is critical for designing next-generation therapies or combination strategies to improve long-term outcomes.
Customer Review
-
Enhanced CAR-T Optimization
Creative Biolabs' CAR-T functional assays enabled critical side-by-side comparisons of cytotoxicity and cytokine release profiles. The reliable data helped optimize our CAR constructs and avoid major development hurdles. - Lie
-
Strategic Preclinical Monitoring
Creative Biolabs' biomarker analysis facilitated a more robust patient monitoring strategy for our preclinical trial. Their flow cytometry services provided precise immunophenotyping, allowing us to detect early signs of antigen loss, which is a key mechanism of relapse. - Dvid
Related Services
To further support your research, we offer a range of complementary services that can be integrated with our CD19 assay portfolio.
Next CAR-T In Vitro Validation
Creative Biolabs' scientists perform a professional multiplex assessment of transfected TCR-T and CAR-T/NK/MA cells to validate their structural robustness and biological functions in vitro. They design and implement a full range of validation analysis services based on your cell therapy engineering goals.
Learn More →
Drug Bioanalysis Service
Creative Biolabs provides comprehensive drug bioanalysis services for both small-molecule and biomacromolecule drugs. These services are crucial for drug discovery and development, providing accurate data for pharmacokinetic and pharmacodynamic characterization.
Learn More →
How to Contact Us
At Creative Biolabs, we are dedicated to accelerating your research and development journey. Our CD19 assay portfolio is more than just a service—it's a partnership built on expertise, quality, and a shared commitment to innovation. Contact our team today to discuss your project and discover how our tailored solutions can help you achieve your goals faster.
Reference
-
Hu, Xiaomeng, et al. "Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice." Nature Communications 14.1 (2023): 2020. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/s41467-023-37785-2
